Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NUVB Nuvation Bio	$2.27 +3.0%	$2.04	$1.54 ▼ $3.97	$770.70M	1.42	2.35 million shs	6.06 million shs
OCS Oculis	$19.50 -0.5%	$17.89	$10.79 ▼ $23.08	$851.41M	0.27	44,001 shs	12,230 shs
SOPH SOPHiA GENETICS	$2.87	$3.00	$2.58 ▼ $5.63	$191.39M	1.03	55,293 shs	19,626 shs
XERS Xeris Biopharma	$5.04 +5.4%	$4.67	$1.96 ▼ $6.07	$788.18M	1.1	1.97 million shs	1.69 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NUVB Nuvation Bio	+3.42%	+0.89%	+3.90%	+15.86%	-22.56%
OCS Oculis	-0.51%	+8.64%	+10.98%	-0.41%	+63.45%
SOPH SOPHiA GENETICS	0.00%	-0.69%	-9.18%	-21.80%	-44.16%
XERS Xeris Biopharma	+5.44%	+3.28%	+14.29%	+31.59%	+161.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NUVB Nuvation Bio	3.7008 of 5 stars	4.6	0.0	0.0	3.4	5.0	0.6
OCS Oculis	2.165 of 5 stars	3.5	3.0	0.0	2.7	0.0	0.6
SOPH SOPHiA GENETICS	2.6701 of 5 stars	3.4	5.0	0.0	2.9	0.0	0.6
XERS Xeris Biopharma	3.7898 of 5 stars	3.4	1.0	4.2	2.8	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NUVB Nuvation Bio	3.17	Buy	$7.83	245.84% Upside
OCS Oculis	3.00	Buy	$31.50	61.54% Upside
SOPH SOPHiA GENETICS	2.75	Moderate Buy	$6.80	136.93% Upside
XERS Xeris Biopharma	2.83	Moderate Buy	$6.25	24.01% Upside

Current Analyst Ratings Breakdown

Latest SOPH, OCS, NUVB, and XERS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $5.00
5/9/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $33.00
5/9/2025	XERS Xeris Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$6.00 ➝ $7.00
4/23/2025	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	NUVB Nuvation Bio	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$6.00
4/23/2025	NUVB Nuvation Bio	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$6.00
4/17/2025	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$29.00 ➝ $32.00
4/17/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/27/2025	NUVB Nuvation Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/13/2025	OCS Oculis	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$37.00 ➝ $41.00
3/13/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NUVB Nuvation Bio	$10.96M	70.34	N/A	N/A	$2.76 per share	0.82
OCS Oculis	$980K	868.78	N/A	N/A	$2.87 per share	6.79
SOPH SOPHiA GENETICS	$67.17M	2.85	N/A	N/A	N/A	∞
XERS Xeris Biopharma	$222.55M	3.54	N/A	N/A	($0.05) per share	-100.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NUVB Nuvation Bio	-$75.80M	-$2.35	N/A	N/A	N/A	N/A	-21.89%	-17.86%	8/4/2025 (Estimated)
OCS Oculis	-$98.92M	-$2.64	N/A	N/A	N/A	-8,043.28%	-71.31%	-56.85%	N/A
SOPH SOPHiA GENETICS	-$78.98M	-$1.00	N/A	N/A	N/A	-110.71%	-55.06%	-38.33%	8/5/2025 (Estimated)
XERS Xeris Biopharma	-$62.26M	-$0.30	N/A	N/A	N/A	-33.69%	N/A	-17.38%	8/14/2025 (Estimated)

Latest SOPH, OCS, NUVB, and XERS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	OCS Oculis	-$0.51	-$0.77	-$0.26	-$0.77	$0.22 million	$0.32 million
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	-$0.06	+$0.01	-$0.06	$57.61 million	$57.80 million
5/7/2025	Q1 2025	NUVB Nuvation Bio	-$0.16	-$0.16	N/A	-$0.16	$0.42 million	$3.08 million
5/6/2025	Q1 2025	SOPH SOPHiA GENETICS	-$0.21	-$0.26	-$0.05	-$0.26	$16.76 million	$17.78 million
3/11/2025	Q4 2024	OCS Oculis	-$0.48	-$0.76	-$0.28	-$0.76	$0.21 million	N/A
3/4/2025	Q4 2024	SOPH SOPHiA GENETICS	-$0.23	-$0.23	N/A	-$0.23	$17.71 million	$17.73 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NUVB Nuvation Bio	N/A	9.57	9.57
OCS Oculis	0.01	4.02	4.02
SOPH SOPHiA GENETICS	0.12	3.80	3.59
XERS Xeris Biopharma	N/A	1.79	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NUVB Nuvation Bio	61.67%
OCS Oculis	22.30%
SOPH SOPHiA GENETICS	31.59%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
NUVB Nuvation Bio	29.93%
OCS Oculis	N/A
SOPH SOPHiA GENETICS	4.88%
XERS Xeris Biopharma	6.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NUVB Nuvation Bio	60	340.26 million	319.50 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable
SOPH SOPHiA GENETICS	520	66.69 million	62.19 million	Not Optionable
XERS Xeris Biopharma	290	156.39 million	142.28 million	Optionable

SOPH, OCS, NUVB, and XERS Headlines

Recent News About These Companies

Millennium Management LLC Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 29 at 3:38 AM | marketbeat.com

BNP Paribas Financial Markets Acquires Shares of 100,012 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 28 at 3:16 AM | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Rating Lowered to Hold at Wall Street Zen

May 24, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Downgraded to "Hold" Rating by Wall Street Zen

May 23, 2025 | americanbankingnews.com

Xeris Announces Details for Analyst & Investor Day

May 20, 2025 | businesswire.com

Stonepine Capital Management LLC Makes New $618,000 Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 20, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by D. E. Shaw & Co. Inc.

May 20, 2025 | marketbeat.com

Leerink Partnrs Weighs in on Xeris Biopharma Q2 Earnings

May 17, 2025 | marketbeat.com

Parkman Healthcare Partners LLC Increases Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 16, 2025 | marketbeat.com

Schonfeld Strategic Advisors LLC Lowers Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 13, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now

May 12, 2025 | msn.com

Driehaus Capital Management LLC Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 12, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ...

May 9, 2025 | finance.yahoo.com

Tudor Investment Corp ET AL Reduces Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

May 9, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (XERS) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Xeris Biopharma Reports Record First Quarter 2025 Financial Results

May 8, 2025 | businesswire.com

4XERS : Earnings Outlook For Xeris Biopharma Holdings

May 7, 2025 | benzinga.com

Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings

May 7, 2025 | seekingalpha.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Position Reduced by Caxton Corp

May 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SOPH, OCS, NUVB, and XERS Company Descriptions

Nuvation Bio NYSE:NUVB

$2.26 +0.07 (+2.95%)

Closing price 05/29/2025 03:59 PM Eastern

Extended Trading

$2.26 -0.01 (-0.22%)

As of 05/29/2025 07:57 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Oculis NASDAQ:OCS

$19.50 -0.10 (-0.51%)

As of 05/29/2025 04:00 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

SOPHiA GENETICS NASDAQ:SOPH

$2.87 0.00 (0.00%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$2.89 +0.02 (+0.70%)

As of 05/29/2025 05:00 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Xeris Biopharma NASDAQ:XERS

$5.04 +0.26 (+5.44%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$5.10 +0.05 (+1.09%)

As of 05/29/2025 07:47 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time